Biochemical Engineering Special Interest Group
biological engineering professionals
06 July 2017

Oxford BioMedica and Novartis build on CAR-T supply deal

Oxford has announced a supply deal with Novartis for its CAR-T personalized leukemia and said today it will get $10 million up front and up to $100 million over three years for its services. Better yet, based on their original 2014 agreement, Oxford says it is slated to get “undisclosed royalties” on sales of the drug. Source: Fierce Biotech 6/7/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).